ライフサイエンスコーパス: streptozotocin

1 e graft loss, the animals were injected with streptozotocin.

2 HG was induced by consecutive injection of streptozotocin.

3 sculature and increased after treatment with streptozotocin.

4 ing Hes3 exhibited increased islet damage by streptozotocin.

5 ld male Wistar rats by injection of 65 mg/kg streptozotocin.

6 was induced by intraperitoneal injection of streptozotocin.

7 or 0.1 mg/kg CNTF before receiving 80 mg/kg streptozotocin.

8 duced in Wistar rats by an i.p. injection of streptozotocin.

9 ed in rats via an intravascular injection of streptozotocin.

10 were rendered equally diabetic with low-dose streptozotocin.

11 T1D was initiated with streptozotocin.

12 ellitus was induced in male FVB/N mice using streptozotocin.

13 and 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g on d

14 n of standardised high-fat diet and low-dose streptozotocin (25mgkg(-1), i.p.) in rats.

15 (n = 8), after induction of type 1 diabetes (streptozotocin [50 mg/kg] intraperitoneally, 5 d), and a

16 7Bl/6J mice by intraperitoneal injections of streptozotocin (60 mg/kg).

17 A high-fat diet and low-dose streptozotocin administration were used to induce a type

18 rosis factor alpha (TNF-alpha) 4 weeks after streptozotocin administration, the retina of REDD1 knock

19 ld-type (WT) C57BL/6 and MBL-null mice after streptozotocin administration.

20 ice was measured weekly from days 0-28 after streptozotocin administration.

21 sphorylation only in WT mice, in contrast to streptozotocin and IL1beta.

22 ar hypertrophy were each blunted in EP1(-/-) streptozotocin and OVE26 cohorts compared with wild-type

23 knockout mice (EP1(-/-)) diabetic using the streptozotocin and OVE26 models.

24 ly eNOS(-/-) mice, had diabetes induced with streptozotocin and then were treated with/without a sele

25 rhesus macaques were rendered diabetic with streptozotocin and underwent islet allotransplantation.

26 myocyte-specific overexpression of GCH1 with streptozotocin, and control animals were given citrate b

27 eficient diet, mice on a high-fat diet given streptozotocin, and mice with disruption of Pten in hepa

28 iabetes was induced) were made diabetic with streptozotocin, and some were given Ret-NH2 once per wee

29 The same mice given low doses of streptozotocin are a model of type 2 diabetes (T2D), dev

30 iple time points after diabetes induction by streptozotocin as assessed by protein levels of microtub

31 Treatment of TRPC6-deficient mice with streptozotocin caused severe reduction of cardiac contra

32 -transgenic (Ntg) and tau-knockout mice with streptozotocin, causing type 1 diabetes-like disease (T1

33 rved a pronounced drop in graft volume after streptozotocin challenge as assessed by MRI.

34 h early type 2 DN and in three mouse models (streptozotocin DBA/2, C57BLKS db/db, and eNOS-deficient

35 In streptozotocin diabetic mice, TRIB3 MOE exacerbated, whe

36 re able to normalize blood glucose levels in streptozotocin diabetic NOD/SCID mice.

37 Streptozotocin diabetic rats (n = 19), previously subjec

38 ural tissues (sciatic nerve, spinal cord) of streptozotocin diabetic rats and mice.

39 Streptozotocin diabetic rats treated daily with heparin

40 High-fat/low-dose streptozotocin diabetic rats were used to examine diabet

41 livers of fasted as well as in high-fat-diet-streptozotocin diabetic rats, in which CREB is constitut

42 nd spinal cord oxidative-nitrative stress in streptozotocin diabetic rats.

43 ning hyperglycemia and hypercholesterolemia (streptozotocin diabetic, apoE-deficient mice), renal STA

44 r treatment with either vehicle (control) or streptozotocin (diabetic).

45 ia (DRG), and the trigeminal ganglia (TG) of streptozotocin-diabetic and healthy control rats.

46 .p.) effectively suppressed BRB breakdown in streptozotocin-diabetic Brown Norway rats.

47 Recipient streptozotocin-diabetic C57BL/6 mice were transplanted w

48 After diabetes, streptozotocin-diabetic mice with heterozygous ATGL defi

49 r beneficial to cardiac function, we studied streptozotocin-diabetic mice with heterozygous ATGL defi

50 NA (D-loop) were analyzed in the retina from streptozotocin-diabetic rats maintained in poor glycemic

51 In streptozotocin-diabetic rats, all cocoa autolysates sign

52 ients and in aorta and carotid arteries from streptozotocin-diabetic versus nondiabetic C57BL/6 mice.

53 protein (CHOP)(-/-) mice made diabetic with streptozotocin displayed less severe sciatic nerve oxida

54 er, NHERF2, which were down-regulated in the streptozotocin group.

55 ard diabetes mouse model (high-fat diet plus streptozotocin [HFD/STZ]) to induce a mild increase in b

56 with streptozotocin, or both in combination (streptozotocin/HFD).

57 ved hyperglycemia and glucose intolerance in streptozotocin, high-fat diet-fed, and db/db diabetic mi

58 ta and hepatocellular carcinogenesis using a streptozotocin-high fat diet (STZ-HFD) induced nonalcoho

59 diabetic patients and diabetic mouse models (streptozotocin/high-fat diet-induced and db/db mice), mi

60 DM was induced with 50 mg/kg intraperitoneal streptozotocin in 56 male Wistar rats.

61 2 diabetes mellitus was induced by low-dose streptozotocin in guinea pigs rendered glucose intoleran

62 he hyperglycemia and insulin loss induced by streptozotocin in mice.

63 Diabetes was induced using streptozotocin in wild-type and netrin-1 transgenic anim

64 reatment with the pancreatic beta-cell toxin streptozotocin induced hyperglycemia and raised plasma g

65 icant, progressive inner retinal thinning in streptozotocin-induced "type 1" and B6.BKS(D)-Lepr(db)/J

66 itoneal glucose tolerance tests in mice with streptozotocin-induced (type 1) diabetes and in a non-ge

67 otransplantation under the kidney capsule of streptozotocin-induced 8- to 10-week-old male athymic nu

68 injection of BTP2 exacerbates albuminuria in streptozotocin-induced and Akita diabetic mice.

69 l and Western blot studies were performed in streptozotocin-induced and control Sprague-Dawley female

70 ith increased O2(*-) production in aortas of streptozotocin-induced and genetically induced Ins2(Akit

71 ndependent animal models of diabetes: db/db, streptozotocin-induced and mice fed a high-fat diet.

72 Experimental diabetes (streptozotocin-induced and ob/ob mice) or chemical sympa

73 assessed whether CNTF protects mice against streptozotocin-induced diabetes (a model of type 1 diabe

74 ofiling of glomeruli isolated from rats with streptozotocin-induced diabetes and controls.

75 diabetes, examining the kidneys of rats with streptozotocin-induced diabetes and kidney cells exposed

76 ively expressed in beta cells prevented both streptozotocin-induced diabetes and the metabolic defici

77 In conclusion, CNTF protects mice against streptozotocin-induced diabetes by increasing pancreatic

78 % (P < 0.01) in apoE knockout (KO) mice with streptozotocin-induced diabetes consuming an atherogenic

79 Mice with streptozotocin-induced diabetes developed profound heart

80 Subjecting Nox5(pod+) mice to streptozotocin-induced diabetes further exacerbated thes

81 volved in leukostasis in the early stages of streptozotocin-induced diabetes in mice by direct observ

82 , we assessed the consequence of 4 months of streptozotocin-induced diabetes in wild type (+/+) and C

83 Streptozotocin-induced diabetes increased glomerular cap

84 onsecutive days in an in vivo mouse model of streptozotocin-induced diabetes inhibited the loss of ti

85 For this purpose, rats with streptozotocin-induced diabetes mellitus (STZ-DM) were t

86 Streptozotocin-induced diabetes mellitus in animals lead

87 Streptozotocin-induced diabetes mellitus in mice was stu

88 the corneal clock, we studied the effects of streptozotocin-induced diabetes on the mitosis of epithe

89 In the absence of hypertension, streptozotocin-induced diabetes resulted in a 14-fold in

90 p53inp2 exhibited enhanced muscle wasting in streptozotocin-induced diabetes that was dependent on au

91 tic RAGE apoE double-knockout (KO) mice with streptozotocin-induced diabetes were treated with the AG

92 c-Rel-deficient mice are resistant to streptozotocin-induced diabetes, a drug-induced model of

93 transplanted into immunodeficient mice with streptozotocin-induced diabetes, and glycemia was initia

94 GR5 dual agonist INT-767 to DBA/2J mice with streptozotocin-induced diabetes, db/db mice with type 2

95 In a model of streptozotocin-induced diabetes, miR-146a(-/-) mice show

96 In rats with streptozotocin-induced diabetes, nitric oxide (NO) bioav

97 were able to protect recipient mice against streptozotocin-induced diabetes, restoring a physiologic

98 in D (CypD)-deficient mice (Ppif (-/-)) with streptozotocin-induced diabetes, we observed an increase

99 nal brush border membrane (BBM) of mice with streptozotocin-induced diabetes.

100 iferative islet cells and with resistance to streptozotocin-induced diabetes.

101 g were evaluated in C57BL/6J adult mice with streptozotocin-induced diabetes.

102 hyperglycemia and ex vivo, in a rat model of streptozotocin-induced diabetes.

103 iminished opioid responsiveness in rats with streptozotocin-induced diabetes.

104 cible human Nox5 transgenic mouse exposed to streptozotocin-induced diabetes.

105 in situ and by glycemic control in rats with streptozotocin-induced diabetes.

106 lar leakage in both early and late stages of streptozotocin-induced diabetes.

107 c pancreata were transplanted into mice with streptozotocin-induced diabetes.

108 ects, and granulation tissues from mice with streptozotocin-induced diabetes.

109 SCHAD knockout (SCHADKO) mice into mice with streptozotocin-induced diabetes.

110 Nondiabetic (N) and streptozotocin-induced diabetic (D) rats underwent 4-h i

111 The study was performed in streptozotocin-induced diabetic (db/db) mice.

112 iabetes-prone BioBreeding/Worcester rats and streptozotocin-induced diabetic (STZ-D) rats and compare

113 Finally, streptozotocin-induced diabetic and uninephrectomized TL

114 n diabetic macrovascular and renal injury in streptozotocin-induced diabetic apolipoprotein E(-/-) mi

115 f combined hyperglycemia and hyperlipidemia (streptozotocin-induced diabetic apolipoprotein E-deficie

116 e of BALB/c islet allografts transplanted in streptozotocin-induced diabetic C57BL/6 mice was 41.2 +/

117 in skeletal muscle is sufficient to mitigate streptozotocin-induced diabetic cardiomyopathy through a

118 xpression of EcSOD is sufficient to mitigate streptozotocin-induced diabetic cardiomyopathy.

119 from mice subjected to prolonged fasting or streptozotocin-induced diabetic ketoacidosis.

120 The study was performed in streptozotocin-induced diabetic mice (C57BL/6).

121 5 islets were transplanted into the liver of streptozotocin-induced diabetic mice (H-2) via the porta

122 Deprivation of insulin in streptozotocin-induced diabetic mice decreased mitochond

123 m CSCs cultured from the cardiac biopsies of streptozotocin-induced diabetic mice displayed impaired

124 Low-dose streptozotocin-induced diabetic mice exhibited increased

125 jected intraperitoneally in immune competent streptozotocin-induced diabetic mice for therapeutic eff

126 Streptozotocin-induced diabetic mice had reduced blood f

127 h db/m+ and db/db CAT-Tg mice and in RPTs of streptozotocin-induced diabetic mice in which insulin re

128 Control and streptozotocin-induced diabetic mice were therefore admi

129 In streptozotocin-induced diabetic mice, 1,25-VitD3 also pr

130 their capacity to regulate blood glucose in streptozotocin-induced diabetic mice, indicating that ad

131 In the retinas of streptozotocin-induced diabetic mice, retinal apoptosis

132 In streptozotocin-induced diabetic mice, TXNIP knockdown to

133 R-29a levels in primary renal glomeruli from streptozotocin-induced diabetic mice.

134 ere transplanted under the kidney capsule of streptozotocin-induced diabetic mice; viability, functio

135 of data from aortic vessels in the low-dose streptozotocin-induced diabetic mouse model (10 animals)

136 In parallel, using streptozotocin-induced diabetic mouse model, we found th

137 suppression would lead to normoglycemia in a streptozotocin-induced diabetic mouse model.

138 dimensional imaging in vivo and in situ in a streptozotocin-induced diabetic mouse model.

139 ncomitant beta-cell survival and number in a streptozotocin-induced diabetic mouse model.

140 ere transplanted under the kidney capsule of streptozotocin-induced diabetic NM.

141 Experiments using streptozotocin-induced diabetic Rab38 knockout and contr

142 that, by 4 weeks after diabetes onset in the streptozotocin-induced diabetic rat model, there is a la

143 ed from the delivery systems were studied in streptozotocin-induced diabetic rat model.

144 cells exposed to hyperglycemia as well as in streptozotocin-induced diabetic rat retinas.

145 Streptozotocin-induced diabetic rats (STZ-rats) were tre

146 retinal vascular leakage and leukostasis in streptozotocin-induced diabetic rats and in Akita mice.

147 Studies were conducted in streptozotocin-induced diabetic rats and in cultured ret

148 gated whether early retinal abnormalities in streptozotocin-induced diabetic rats are alleviated by p

149 Ins2(Akita) diabetic mice and streptozotocin-induced diabetic rats exhibited marked re

150 n on oxidative stress and organ histology in streptozotocin-induced diabetic rats fed a high fat (HF)

151 Streptozotocin-induced diabetic rats showed decreased a-

152 ubcutaneously into nondiabetic (control) and streptozotocin-induced diabetic rats to elicit a granula

153 tions in PA mass from retinas of control and streptozotocin-induced diabetic rats were determined by

154 tein expression was increased in proteinuric streptozotocin-induced diabetic rats.

155 se 1 (LSD1) were measured in the retina from streptozotocin-induced diabetic rats.

156 with Keap1 was investigated in the retina of streptozotocin-induced diabetic rats.

157 Islet allograft survival was investigated in streptozotocin-induced diabetic recipient BALB/c (H-2d)

158 lted in reversion to normoglycemia in 50% of streptozotocin-induced diabetic recipients (n=12) compar

159 lantable chamber normalized blood glucose in streptozotocin-induced diabetic rodents for up to 3 mo.

160 In streptozotocin-induced diabetic SCID/beige mice, the inj

161 Here, we show that in Streptozotocin-induced diabetic wild type mice, hypo-pho

162 in vitro podocyte culture experiments and a streptozotocin-induced DKD model in FHL2 gene-knockout m

163 In a rat model of streptozotocin-induced hyperglycemia, we found that endo

164 nd wild-type controls were transplanted into streptozotocin-induced hyperglycemic NOD-scid IL2Rgamma(

165 to four groups: 1) nondiabetic (NONDIAB), 2) streptozotocin-induced insulin deficiency (STZ), 3) STZ

166 In a streptozotocin-induced model of T1D in mice, ML351 preve

167 Here, we employed a streptozotocin-induced rat model (STZ-DM) of uncontrolle

168 t effects of leptin replacement therapy in a streptozotocin-induced rat model of DKA.

169 SNP administered for 3 weeks to mice with streptozotocin-induced type 1 diabetes ameliorated kidne

170 We worked with mice with streptozotocin-induced type 1 diabetes and with nondiabe

171 In a mouse model of streptozotocin-induced type 1 diabetes, (52)Mn(2+) uptak

172 In streptozotocin-induced type 1 diabetes, podocyte-specifi

173 We conducted studies in animals (streptozotocin-induced type 1 diabetic mice) and cellula

174 In streptozotocin-induced type 1 diabetic mice, there was a

175 ieu of vascular growth factors is altered in streptozotocin-induced type 1 diabetic mice, with decrea

176 of HIPK2, was decreased in the glomeruli of streptozotocin injected diabetic mice.

177 on of p53 in the renal cortex of control and streptozotocin-injected diabetic mice.

178 nduced in FVB mice fed on a high-fat diet by streptozotocin injection followed by ligation of the lef

179 Streptozotocin injection in rats led to a progressive PP

180 t for 16 weeks, then either made diabetic by streptozotocin injection or kept normoglycemic.

181 After streptozotocin injection to induce diabetes, wild-type m

182 that, upon induction of diabetes type 1 via streptozotocin injection, Cyp4a14KO male mice developed

183 Ten weeks after streptozotocin injection, diabetic mice showed significa

184 ition of type 1 diabetes mellitus induced by streptozotocin injection.

185 perior colliculus was observed 6 weeks after streptozotocin injection.

186 lammatory cells and were made diabetic using streptozotocin injections.

187 y, autoimmunity, or diabetogenic agents like streptozotocin may confound understanding alloimmunity i

188 caused by diet-induced insulin resistance or streptozotocin-mediated beta-cell mass depletion, PKA ac

189 n diabetic CMSCs and in the heart of HFD and streptozotocin mice eliciting, in HFD, DNA demethylation

190 ell mass and regeneration: multiple low-dose streptozotocin (MLDS) and partial pancreatectomy (Ppx).

191 tes in the T cell-mediated multiple low-dose streptozotocin (MLDS) model.

192 Using a streptozotocin mouse model of diabetic retinopathy, we r

193 In genetic (Akita) and pharmacological (streptozotocin) murine models of type 1 diabetes, cardia

194 fects of dietary flaxseed oil or fish oil on streptozotocin-nicotinamide induced diabetic rats were i

195 In addition, streptozotocin-nicotinamide-induced diabetic mice treate

196 f Tg-IGF2 mice with subdiabetogenic doses of streptozotocin or crossing these mice with a transgenic

197 xposed to high-fat diet (HFD), injected with streptozotocin, or both in combination (streptozotocin/H

198 However, when subjected to streptozotocin plus high-fat diet to induce islet inflam

199 Six weeks after streptozotocin premedication, Wistar male rats presentin

200 approach using two exemplar data sets: (a) a streptozotocin rat model (n = 30) of type 1 diabetes and

201 tosis and preserves pancreatic beta-cells in streptozotocin-rendered hyperglycemic mice.

202 t pregestational diabetes in mice induced by streptozotocin significantly increased 4-hydroxynonenal

203 that otherwise dominate the variation in the streptozotocin study, which then allowed recovery of bio

204 d with a single intraperitoneal injection of streptozotocin (STZ) (n = 10); group 2 (G2): rats were n

205 yofilaments, restoring Ca(2+) sensitivity in streptozotocin (STZ) diabetic cardiac muscles.

206 oxidative stress and genotoxicity induced by streptozotocin (STZ) diabetic rats.

207 C57BL/6J mice were rendered diabetic with streptozotocin (STZ) for 1, 3, or 5 months' duration.

208 tic mice induced by high fat diet (HFD) plus streptozotocin (STZ) in C57BL/6J mice for 13 weeks start

209 atic beta-cells were chemically destroyed by streptozotocin (STZ) in Gcgr(-/-):Glp-1r(-/-) mice and i

210 ned to two groups: diabetic group induced by streptozotocin (STZ) injection or normoglycemic controls

211 ignals were confirmed in diabetic mice after streptozotocin (STZ) injection.

212 Here, we used multiple low-dose (MLD) streptozotocin (STZ) injections and the NOD mouse model

213 in K knockout mice were rendered diabetic by streptozotocin (STZ) injections.

214 thase (Nos3)-deficient mice by five low-dose streptozotocin (STZ) injections.

215 Streptozotocin (STZ) is widely used as diabetogenic agen

216 is, and inflammation in the experimental rat streptozotocin (STZ) model of diabetic retinopathy (DR).

217 tion, adult male Wistar rats received either streptozotocin (STZ) to induce uDM (STZ-DM) or vehicle a

218 islet cell survival and prevents diabetes in streptozotocin (STZ) treated rats.

219 knockout (TLR4KO) mice were made diabetic by streptozotocin (STZ) treatment, and bladder contractile

220 Two groups of Wistar rats were injected with streptozotocin (STZ) two days after birth using 45 and 9

221 Diabetes was induced by injection of streptozotocin (STZ), and retinal blood flow rate was me

222 In response to multiple low-dose streptozotocin (STZ), hep-tg animals developed less seve

223 s endogenous beta-cell survival and prevents streptozotocin (STZ)- and obesity-induced diabetes.

224 Normal Sprague-Dawley rats as well as RH or streptozotocin (STZ)-diabetic rats received bilateral VM

225 ced model of obesity and a nicotinamide (NA)-streptozotocin (STZ)-HFD-induced model of mild type 2 di

226 and insulin resistance and nicotinamide (NA)-streptozotocin (STZ)-HFD-induced type 2 diabetes.

227 of the PI 3-kinase/Akt pathway and increased streptozotocin (STZ)-induced apoptosis; conversely, over

228 Thus, in a rat model of streptozotocin (STZ)-induced chronic type 1 diabetes mel

229 lodeficiency of Klotho (KL(+/-)) exacerbated streptozotocin (STZ)-induced diabetes (a model of T1DM),

230 Four beagle dogs with streptozotocin (STZ)-induced diabetes and four healthy d

231 or 3 wk dramatically reduced the severity of streptozotocin (STZ)-induced diabetes in nonobese diabet

232 Streptozotocin (STZ)-induced diabetes is the most common

233 d alpha-cell voltage-gated ion channels in a streptozotocin (STZ)-induced diabetes model that lead to

234 tin dose-response study in C57Bl/6 mice with streptozotocin (STZ)-induced diabetes to determine a lep

235 d glucose and insulin tolerance in mice with streptozotocin (STZ)-induced diabetes, an insulin-defici

236 diet-induced obese (DIO) mice, and rats with streptozotocin (STZ)-induced diabetes.

237 and HYAL1 knockout (KO) mice with or without streptozotocin (STZ)-induced diabetes.

238 9 would normalize cutaneous wound healing in streptozotocin (STZ)-induced diabetic (STZ-diabetic) mic

239 n, and suppressed atherosclerotic lesions in streptozotocin (STZ)-induced diabetic ApoE(-/-) mice.

240 stigated in vivo by administration of PP2 to streptozotocin (STZ)-induced diabetic DBA2/J mice.

241 We analyzed the phenotype of nondiabetic and streptozotocin (STZ)-induced diabetic homozygous PKC-alp

242 found that reduced BK-beta(1) expression in streptozotocin (STZ)-induced diabetic mouse arteries and

243 tic activity in sucrose-challenged low-dosed streptozotocin (STZ)-induced diabetic rats and db/db mic

244 early alterations within the bone marrow of streptozotocin (STZ)-induced diabetic rats following tre

245 radix puerariae, reduces diabetic injury in streptozotocin (STZ)-induced diabetic rodent models.

246 Age-matched control or streptozotocin (STZ)-induced diabetic, and db/db mice wi

247 ic backgrounds were protected from high-fat/ streptozotocin (STZ)-induced hyperglycemia that was acco

248 pment of glomerulopathy and albuminuria upon streptozotocin (STZ)-induced hyperglycemia.

249 In a rat model of streptozotocin (STZ)-induced T1D, GHRH receptor expressi

250 We show here that during streptozotocin (STZ)-induced T1D, the nucleotide-binding

251 adoptively transferred to multiple low-dose streptozotocin (STZ)-induced T1DM.

252 tosolic form of Trx) in the VMH of rats with streptozotocin (STZ)-induced type 1 diabetes.

253 rostaglandin (PG) E(2) signaling pathways in streptozotocin (STZ)-induced type 1 diabetes.

254 in isolated heart mitochondria from Sham and streptozotocin (STZ)-induced type 1 diabetic (T1DM) guin

255 Studies were performed in streptozotocin (STZ)-injected DBA/2J mice fed a high-fat

256 Experimental DR in streptozotocin (STZ)-injected rodents is described as an

257 Gcgr(-/-)) do not develop diabetes following streptozotocin (STZ)-mediated ablation of insulin-produc

258 In both streptozotocin (STZ)-treated mice and cells in culture e

259 tablished in vitro experimental models using streptozotocin (STZ)-treated primary pancreatic islet ce

260 three mouse models of diabetic nephropathy: streptozotocin (STZ)-treated, OVE26, and Akita mice.

261 Long Evans rats were rendered diabetic with streptozotocin (STZ).

262 Type 1 diabetes was induced in mice using streptozotocin (STZ).

263 leted of insulin with the diabetogenic agent streptozotocin (STZ).

264 e using repeated injections of a low dose of streptozotocin (STZ).

265 lows: 1) non-ligated control (NL, n = 6); 2) streptozotocin (STZ, n = 8); 3) STZ and melatonin (STZ+M

266 Dahl Salt-Sensitive rats by an injection of streptozotocin (STZ-SS).

267 genitor cells using mouse models of chronic (streptozotocin [STZ]-induced diabetes) and acute (ischem

268 e of these pathways, rats were injected with streptozotocin to induce diabetes and implanted subcutan

269 Male C57BL/6 mice were injected streptozotocin to induce diabetes.

270 nsgenic (miR-133aTg) mice were injected with streptozotocin to induce diabetes.

271 mic nucleus (VMN) received either vehicle or streptozotocin to induce uncontrolled insulin-deficient

272 After the induction of diabetes with streptozotocin, transgenic mice had less albuminuria tha

273 nhanced glucose control in the high fat fed, streptozotocin treated and NONcNZO10/LtJ mouse models of

274 rat pancreatic islet cells transplanted into streptozotocin-treated diabetic C57BL/6 mice, islets pre

275 edly hypoglycemic range in overnight-fasted, streptozotocin-treated Gcgr(-/-) mice.

276 level also was observed in overnight-fasted, streptozotocin-treated ghrelin receptor-null mice that w

277 Streptozotocin-treated male Wistar rats were fed a chole

278 rown adipose tissue (BAT) can correct T1D in streptozotocin-treated mice (both immune competent and i

279 Streptozotocin-treated mice had increased pacemaker cell

280 Streptozotocin-treated mice showed increased levels of s

281 nse were diminished in diabetic retinas from streptozotocin-treated mice.

282 le for the cognitive decline observed in Ntg streptozotocin-treated mice.

283 Streptozotocin-treated MM-VV mice and WT mice infused wi

284 For animal studies, we used streptozotocin-treated rats after 2 and 8 months of diab

285 Livers from streptozotocin-treated T1D rats demonstrated a significa

286 ogy in humans, we examined brain tissue from streptozotocin-treated type 1 diabetic adult male vervet

287 via p63/REDD1 pathway in skeletal muscle of Streptozotocin-treated wild type mice.

288 male mice developed worse renal disease than streptozotocin-treated wild-type mice, characterized by

289 rease fasting blood glucose at 30 mg/kg in a streptozotocin-treated, diet-induced obesity mouse pharm

290 In Myostatin(-/-) mice however, Streptozotocin treatment did not reduce Akt phosphorylat

291 Hyperglycemia induced by streptozotocin treatment impaired lesion size reduction

292 rved in Myostatin(-/-) muscle in response to Streptozotocin treatment.

293 fficiency in myocardium rendered diabetic by streptozotocin treatment.

294 atic insulin content after multiple low-dose streptozotocin treatment.

295 TAT and suppression of TH in the heart after streptozotocin was administered.

296 function (Sema3a(+)) mice made diabetic with streptozotocin, we demonstrate that sema3a is pathogenic

297 M1R-deficient mice made diabetic with streptozotocin were protected from physiological and str

298 tochemistry, and mice rendered diabetic with streptozotocin were used to validate the proapoptotic ge

299 developed fatal diabetic ketoacidosis after streptozotocin, whereas GcgR(-/-) mice with similar beta

300 ritoneal space of C57BL/6J mice treated with streptozotocin, which is an animal model for chemically